Provided by Tiger Trade Technology Pte. Ltd.

CorMedix Inc.

7.13
-0.1000-1.38%
Pre-market: 7.320.1900+2.66%07:50 EDT
Volume:868.60K
Turnover:6.24M
Market Cap:561.77M
PE:3.50
High:7.34
Open:7.26
Low:7.12
Close:7.23
52wk High:17.43
52wk Low:6.13
Shares:78.79M
Float Shares:73.69M
Volume Ratio:0.96
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.04
EPS(LYR):2.04
ROE:66.56%
ROA:21.21%
PB:1.39
PE(LYR):3.50

Loading ...

RBC Capital Sticks to Its Buy Rating for Cormedix (CRMD)

TIPRANKS
·
Apr 09

CorMedix to join Needham Virtual Healthcare Conference fireside chat and investor meetings

Reuters
·
Apr 07

CorMedix affirms FY26 revenue view of $300M-$320M, consensus $308.7M

TIPRANKS
·
Mar 07

CorMedix price target lowered to $13 from $15 at Leerink

TIPRANKS
·
Mar 07

Cormedix (CRMD) Receives a Buy from RBC Capital

TIPRANKS
·
Mar 06

CorMedix Is Maintained at Buy by Needham

Dow Jones
·
Mar 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Altimmune (ALT), Rhythm Pharmaceuticals (RYTM) and Cormedix (CRMD)

TIPRANKS
·
Mar 06

CorMedix Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 05

CORRECTED-Pharmaceutical firm CorMedix misses Q4 profit expectations, reiterates 2026 revenue forecast

Reuters
·
Mar 05

Cormedix Q4 EPS $0.18 May Not Compare To $0.82 Estimate, Sales $128.600M Beat $127.022M Estimate

Benzinga
·
Mar 05

CorMedix’s CRMD Q4 net revenue hits USD 128.6 million, up 312%

Reuters
·
Mar 05

CorMedix Q4 Operating Expenses USD -48.182 Million

THOMSON REUTERS
·
Mar 05

CorMedix Inc: Q4 Net Revenue $128.6 Mln

THOMSON REUTERS
·
Mar 05

CorMedix Q4 Basic EPS USD 0.18

THOMSON REUTERS
·
Mar 05

CorMedix Inc - Reiterates 2026 Guidance

THOMSON REUTERS
·
Mar 05

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire
·
Mar 05

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 05

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

GlobeNewswire
·
Mar 02

CorMedix's Growth Outlook Hinges on Trial Data, Prophylaxis Opportunity, RBC Says

MT Newswires Live
·
Feb 12

CorMedix Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Feb 11